Company: DVAX
Filing Date: 2025-04-07
Form Type: PREC14A
Source: 0001193125-25-074629
Chunk: 12

Company: DYNAVAX TECHNOLOGIES CORP
Filing Date: 2025-04-07
Form: PREC14A
Chunk 12
---
 us to conclude
that the Deep Track Nominees should serve as directors of the Company are also set forth below.

Brett Erkman, age 44.

Since October 2022, Brett Erkman has served as a Managing Director of Deep Track Capital, an investment firm focused on the life sciences.
Prior to Deep Track Capital, he was a biotechnology investor at Great Point Partners from October 2006 through April 2022. Previously, Mr. Erkman was a sell side associate at ThinkEquity Partners and a financial analyst at Abbott Laboratories.
Mr. Erkman holds a B.S. in Finance from DePaul University.

Mr. Erkman has been analyzing investments in biotechnology companies for
20 years. As such, he would bring many skills to his service on the Board of directors including financial acumen, strategic thinking, an understanding of risk management, and insight into the health care markets. In particular, Mr. Erkman’s
history with Dynavax as an investor dates back to middle of the HBV-16 trial, giving him a long-term perspective on the

14

history of the company’s lead asset. This history, combined with his experience as an investor in other vaccine-focused companies, gives him a deep understanding of the difficulties and
complexities of vaccine development from technical, regulatory, and commercial perspectives. Furthermore, Mr. Erkman’s long history as a buy-side investor would offer a unique opportunity for other
directors to hear precise and highly informed guidance on how public market investors would interpret and react to disclosures, forecasts, strategies, and expectations issued by the Company.

Jeffrey Farrow, age 63.

Jeffrey
Farrow has served as Chief Financial Officer and Chief Strategy Officer of Tarsus Pharmaceuticals, Inc. since April 2023. Mr. Farrow also serves as a board member of Clover Biotherapeutics, a position he has held since September 2021.
Mr. Farrow previously served as Chief Financial Officer of Global Blood Therapeutics, Inc., a biopharmaceutical company, from April 2016 until December 2022 when it was acquired by Pfizer. At Global Blood Therapeutics, he was part of the team
responsible for the successful regulatory approval and commercial launch of Oxbryta for the treatment of sickle cell disease. Prior to that, Mr. Farrow served as chief financial officer of ZS Pharma, Inc., a biopharmaceutical company, which was
acquired by AstraZen